Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
Earnings and Valuation
This table compares Xenon Pharmaceuticals and Nurix Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xenon Pharmaceuticals | N/A | N/A | -$345.91 million | ($4.74) | -7.93 |
| Nurix Therapeutics | $83.98 million | 34.36 | -$264.46 million | $2.31 | 11.43 |
Nurix Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Xenon Pharmaceuticals has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Xenon Pharmaceuticals and Nurix Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xenon Pharmaceuticals | 1 | 1 | 12 | 1 | 2.87 |
| Nurix Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
Xenon Pharmaceuticals currently has a consensus price target of $70.14, suggesting a potential upside of 86.57%. Nurix Therapeutics has a consensus price target of $34.79, suggesting a potential upside of 31.71%. Given Xenon Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Xenon Pharmaceuticals is more favorable than Nurix Therapeutics.
Insider and Institutional Ownership
95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Xenon Pharmaceuticals and Nurix Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xenon Pharmaceuticals | N/A | -43.98% | -41.72% |
| Nurix Therapeutics | 42.01% | 49.34% | 38.61% |
Summary
Nurix Therapeutics beats Xenon Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
